Faisal Rahman
Interventional Cardiology · Baltimore, MDNPI 1215293311
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $23,643 and has fallen 74.2% since, to $6,096 in 2025.
Across 206 payments — averaging $174.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- Edwards Lifesciences$3K
- Abbott$2K
- Boston Scientific$2K
- Medical Device Business Services, Inc.$777
- Abiomed$663
- plus $2K from 14 others
What the payments were for
- Grants$21,00058%
- Travel & lodging$6,52018%
- Food & beverage$8,18523%
- Education$2601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 72 | $25,576 |
| Edwards Lifesciences | 25 | $2,942 |
| Abbott | 27 | $2,441 |
| Boston Scientific | 15 | $2,060 |
| Medical Device Business Services, Inc. | 27 | $777 |
| Abiomed | 9 | $663 |
| Terumo Medical Corporation | 3 | $424 |
| AstraZeneca | 2 | $202 |
| Shockwave Medical, Inc | 4 | $176 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $145 |
| Pfizer | 2 | $142 |
| Acist Medical Systems, Inc. | 1 | $127 |
| Novartis | 3 | $87 |
| Amgen | 3 | $59 |
| Kestra Medical Technology Services, Inc. | 1 | $37 |
| Philips North America LLC | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Cordis US CORP. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$2,598
- TRICLIP$1,535
- Watchman$1,416
- EVOQUE$537
- TR Band$400
- Carto 3$358
- Impella$261
- Optitorque$260
- Heartrail$260
- Glidesheath$260
- Dragonfly OCT$245
- GENERAL VASCULAR ACCESS$130
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$128
- CVI SYSTEMS$127
- AVVIGO Guidance System$126
- VYNDAQEL$123
- iLab Ultrasound Imaging System$122
- PASCAL$117
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$112
How this compares
$35,965 in reported general payments places this provider in the 80th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $37,220 |
| JardianceEmpagliflozin | 36 | $36,550 |
| EntrestoSacubitril/Valsartan | 24 | $26,147 |
| Metoprolol Succinate | 65 | $938 |
| Atorvastatin Calcium | 39 | $515 |
| Losartan Potassium | 16 | $172 |
| Furosemide | 39 | $111 |
| Spironolactone | 21 | $107 |
| Lisinopril | 18 | $99 |
| Amoxicillin | 21 | $41 |
| Amlodipine Besylate | 15 | $29 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $4 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $37,22041 claims |
| NovartisEntresto | $87 | $26,14724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Baltimore
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Diljon ChahalBaltimore$78K
- Jon ResarBaltimore$40K
- Matthew VossBaltimore$33K
- Hooman BakhshiBaltimore$32K
- Daniel AmbinderBaltimore$32K
- Rani HasanBaltimore$22K
- Ajar KocharBaltimore$22K
- Hani AlkhatibBaltimore$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.